Why Clinical Trials Are the Backbone of T1D Progress

Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system attacks insulin-producing beta cells in the pancreas. For decades, the standard of care has been exogenous insulin administration, blood glucose monitoring, and lifestyle management. While these approaches have improved dramatically, they remain management strategies rather than cures. Clinical trials are the engine that moves potential breakthroughs from laboratory discoveries into real-world treatments. They test whether a new therapy—whether an immunomodulatory drug, a beta-cell replacement strategy, or an advanced insulin delivery system—is safe and effective in humans.

Without rigorous clinical trials, even the most promising science stays on the bench. JDRF, originally the Juvenile Diabetes Research Foundation and now simply JDRF International, has long understood this. The organization’s mission is to accelerate life-changing breakthroughs in T1D research, and clinical trials are where that mission is put into practice. JDRF not only funds trials but also shapes their design, recruits participants, and works with regulators to streamline approval pathways.

JDRF’s Multifaceted Approach to Clinical Trial Support

JDRF does not operate a single monolithic clinical-trial program. Instead, it deploys a range of tools—grants, partnerships, infrastructure building, patient engagement, and policy advocacy—to move the needle on T1D therapies. Each of these components reinforces the others, creating a pipeline that efficiently turns scientific insight into clinical impact.

Strategic Funding and Grant Mechanisms

JDRF allocates millions of dollars annually to clinical research. Its grant portfolio covers early-phase proof-of-concept studies (Phase 1), dose-finding and safety trials (Phase 2), and larger efficacy trials (Phase 3). A distinctive feature of JDRF’s approach is its willingness to fund high-risk, high-reward projects that traditional sources such as the NIH might shy away from. For example, the organization’s Industry Discovery and Development Partnerships (IDDP) program co-invests with pharmaceutical and biotechnology companies to de-risk early-stage clinical development. This shared-risk model encourages companies to initiate trials that might otherwise remain on the drawing board.

Beyond direct grants, JDRF also supports clinical trial networks. The JDRF Clinical Trials Network, a consortium of leading academic medical centers, enables multi-site trials with standardized protocols, centralized data management, and rapid enrollment. This infrastructure drastically reduces the time it takes to recruit participants and gather results.

Forging Partnerships Across Sectors

JDRF acts as a bridge between academia, industry, regulatory agencies, and patient communities. Its collaborations range from small biotech startups to global pharmaceutical giants. A notable partnership is with industry leaders on the artificial pancreas, which has already resulted in several FDA-approved hybrid closed-loop systems. By convening stakeholders early, JDRF helps align trial end points, reduce duplication, and accelerate regulatory review.

JDRF also partners with the National Institutes of Health (NIH) through the Type 1 Diabetes TrialNet, an international network dedicated to the prevention, early detection, and intervention of T1D. TrialNet has screened hundreds of thousands of relatives of people with T1D to identify those at risk, enabling prevention trials such as the landmark TN10 study of teplizumab, which delayed clinical T1D by a median of two years.

Engaging Patients and Accelerating Enrollment

One of the biggest bottlenecks in clinical research is patient recruitment. JDRF addresses this through its clinical trial matching tools, online resources, and community outreach initiatives. The JDRF website features a searchable database of trials, and the organization runs awareness campaigns to encourage participation. Patient advocates serve on advisory boards for trial design, ensuring that studies address what matters most to the T1D community: quality of life, convenience, and long-term outcomes.

Furthermore, JDRF has developed the JDRF Research Registry, a platform that connects individuals affected by T1D with researchers seeking volunteers. By lowering barriers to enrollment, JDRF helps trials reach sample sizes faster, cutting costs and shortening development timelines.

Advocacy and Regulatory Pathways

JDRF’s advocacy extends to regulatory agencies like the U.S. Food and Drug Administration (FDA). The organization has pushed for regulatory flexibility in T1D trials—for example, acceptance of continuous glucose monitoring (CGM) data as a primary end point rather than relying solely on HbA1c. This shift has made it easier and faster to evaluate new therapies. JDRF also advocates for adaptive trial designs and accelerated approval pathways for drugs that address unmet medical needs.

Recent Clinical Trials Accelerated by JDRF Support

The impact of JDRF’s strategy is visible across several key areas of T1D research. Below are three examples that highlight the breadth of its involvement.

Immune Therapies: Teplizumab and Beyond

Teplizumab, an anti-CD3 monoclonal antibody developed by Provention Bio (now part of Sanofi), is a landmark T1D therapy. In the TN10 trial—conducted by TrialNet with substantial JDRF support—teplizumab delayed the onset of clinical T1D in at-risk individuals by an average of two years. This was the first therapy ever shown to modify the disease course before diagnosis. The FDA approved teplizumab (brand name Tzield) in 2022 for delaying Stage 3 T1D. JDRF’s early funding and collaboration were instrumental in moving this drug from academic research to regulatory submission.

Building on this success, JDRF is now co-funding trials of combination immune therapies—such as anti-CD3 plus anti-CD20 (rituximab) or anti-thymocyte globulin (ATG) with granulocyte colony-stimulating factor (G-CSF)—aimed at preserving residual beta-cell function in newly diagnosed patients. These trials could lead to cocktails that halt autoimmune attack more effectively than single agents.

Advanced Insulin Delivery and Closed-Loop Systems

The artificial pancreas (or hybrid closed-loop system) is one of the most transformative innovations in T1D management. JDRF has been a core supporter of this technology since its infancy. Through its Industry Discovery and Development Partnerships, JDRF provided early funding and expertise to companies like Medtronic, Tandem Diabetes Care, and Insulet. These efforts culminated in FDA-approved systems that automate insulin delivery based on CGM readings, significantly improving glycemic control and reducing hypoglycemia risk. Current trials are exploring next-generation dual-hormone pumps (insulin plus glucagon) and fully closed-loop systems that require no user input. JDRF’s support for these trials continues to push the envelope toward a “bionic pancreas.”

Beta-Cell Replacement: Encapsulation and Stem Cells

For individuals with severe hypoglycemia unawareness or labile diabetes, beta-cell replacement via whole-pancreas or islet transplantation can be life-changing. However, these procedures require lifelong immunosuppression, which limits their use. JDRF funds numerous trials aimed at making beta-cell replacement safer and more widely available. For example, the organization supports ViaCyte’s (now Vertex) stem cell-derived islet replacement therapy combined with a device that immunoisolates the cells, eliminating the need for immunosuppression. Early-phase trials have shown that these implanted cells can produce insulin in response to glucose. JDRF also funds research into gene-edited pig islets (xenotransplantation) and encapsulated beta cells derived from induced pluripotent stem cells. These approaches, if successful, could provide a functional cure for T1D.

Measuring Success: How JDRF Tracks Clinical Trial Outcomes

JDRF does not simply write checks and wait. The organization actively monitors the progress of the trials it supports through milestone-based grant reviews, data-sharing agreements, and regular reports. Success metrics include not only whether a trial meets its primary end point but also how quickly it enrolls, whether it retains participants, and whether the results lead to further funding or regulatory action. This disciplined oversight ensures that donor dollars are spent efficiently and that lessons from failed trials inform the design of future studies.

From Bench to Bedside: The Value of a Coordinated Pipeline

Perhaps JDRF’s greatest strength is its ability to connect the dots across the entire translational spectrum. A discovery in an academic lab might first receive a small JDRF pilot grant. If results are promising, JDRF may fund a multi-center Phase 1 trial. Then, if safety is established, the organization helps the research team partner with an industry sponsor for later-stage development. This handoff process—smooth because JDRF cultivates relationships with both researchers and commercial partners—reduces the notorious “valley of death” between basic science and marketable therapies.

Challenges and the Road Ahead

Despite progress, significant hurdles remain. Clinical trials for T1D are expensive and time-consuming. Recruiting participants—especially for prevention trials that require screening of unaffected individuals—is difficult. The heterogeneity of T1D itself, which varies by age of onset, genetic background, and immune profile, complicates trial design. JDRF is tackling these challenges head-on by funding biomarker research to stratify patients, investing in decentralized trial technologies (e.g., telemedicine, remote CGM data collection), and pushing for regulatory acceptance of composite end points that capture both glycemic control and quality-of-life measures.

Another frontier is equity in clinical trials. Historically, T1D trials have underenrolled minorities and underserved populations. JDRF has launched initiatives to diversify trial participation, including community-based recruitment strategies and translation of trial materials into multiple languages. The goal is to ensure that future therapies work for everyone, not just a narrow demographic.

What This Means for People Living with T1D

For individuals and families affected by T1D, JDRF’s clinical trial facilitation means that more options are available today than ever before. Therapies that were science fiction a decade ago—immune prevention, automated insulin delivery, stem-cell transplants—are now being tested in humans. And because JDRF actively involves the patient community in trial design, these therapies are more likely to meet real-world needs.

If you or a loved one is interested in participating in a T1D clinical trial, JDRF provides a centralized clinical trials search tool on its website. The site allows you to filter by location, age, and study type. You can also learn more about specific trials through ClinicalTrials.gov, the federal registry that JDRF encourages all its funded investigators to use.

Conclusion: A Future Reshaped by Clinical Trials

JDRF’s work in facilitating clinical trials is a powerful example of how a nonprofit can accelerate medical progress. By combining strategic funding, collaborative partnerships, patient engagement, and regulatory advocacy, JDRF has helped bring therapies to market that directly improve the lives of people with T1D. While a cure remains the ultimate goal, the organization’s efforts have already delivered tangible benefits: fewer hypos, better glucose control, and—with teplizumab—the first-ever disease-modifying intervention. As science advances, JDRF’s commitment to clinical trials will continue to turn hope into reality, one study at a time.